Global Checkpoint Inhibitors for Treating Cancer Market Research Report

Posted by QYRtina on June 22nd, 2018

The Checkpoint Inhibitors for Treating Cancer Market Research report clarifies the past experience and trends, on the basis of these past experiences, it offers the future prediction considering other factors influencing the growth rate. This worldwide report offers the detailed analysis of the important factors such as market dynamics (DROT), PEST, and PORTER which assists the growth of the Checkpoint Inhibitors for Treating Cancer Industry. These past experience and factors assist to build the strategy and future planning of Checkpoint Inhibitors for Treating Cancer Market and hold a place in the competitive world.

The Checkpoint Inhibitors for Treating Cancer industry Market report offers the competitive scenario in the Checkpoint Inhibitors for Treating Cancer industry based on the type of product, applications, and the companies that are present in the Checkpoint Inhibitors for Treating Cancer market, and covers the company profiles, their development policies, lined up products and recent launched along with the SWOT analysis of companies.

To get a complete report sample from this link: http://www.qyresearchglobal.com/goods-1680789.html

This report studies the Checkpoint Inhibitors for Treating Cancer market size (value and volume) by players, regions, product types and end industries, history data 2013-2017 and forecast data 2018-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the "brakes" on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
Those four kinds of checkpoint inhibitors are mainly used to treat melanoma, bladder cancer and others. In 2015, melanoma treatment consumed checkpoint inhibitors took a share of 80.53%. In 2016, melanoma treatment consumed checkpoint inhibitors will be 68153g. Bladder cancer treatment consumed checkpoint inhibitors will be 1978g.
Although YERVOY (ipilimumab), OPDIVO (nivolumab), KEYTRUDA (pembrolizumab) and Tecentriq (atezolizumab) are four indispensable medicines for cancer treatment, they also has many shortages. Firstly, they all have side effect for patient. Secondly, price of checkpoint inhibitors for treating cancer is too expensive. CTLA-4 inhibitors price is about 118.2 USD/mg in 2016. PD-1 inhibitors price is about 28.6 USD/mg in 2016. PD-L1 inhibitors price is about 30.5 USD/mg in 2016. For most patients, the price is unbearable.
The global Checkpoint Inhibitors for Treating Cancer market was 4690 million US$ in 2017 and is expected to 29000 million US$ by the end of 2025, growing at a CAGR of 25.6% between 2018 and 2025.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Checkpoint Inhibitors for Treating Cancer in these regions, from 2013 to 2025, covering
    North America (United States, Canada and Mexico)
    Europe (Germany, UK, France, Italy, Russia and Turkey etc.)
    Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
    South America (Brazil etc.)
    Middle East and Africa (Egypt and GCC Countries)

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include
    Bristol-Myers Squibb(BMS)
    Merck
    Roche
By the product type, the market is primarily split into
    PD-1 Inhibitors
    PD-L1 Inhibitors
    CTLA-4 Inhibitors
By the end users/application, this report covers the following segments
    Melanoma Treatment
    Bladder Cancer Treatment
    Other

The study objectives of this report are:

To study and analyze the global Checkpoint Inhibitors for Treating Cancer market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.

To understand the structure of Checkpoint Inhibitors for Treating Cancer market by identifying its various subsegments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Focuses on the key global Checkpoint Inhibitors for Treating Cancer manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Checkpoint Inhibitors for Treating Cancer with respect to individual growth trends, future prospects, and their contribution to the total market.

To project the value and volume of Checkpoint Inhibitors for Treating Cancer submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

Contact Details:

Company Name: QYResearch CO.,LIMITED | focus on Market Survey and Research

Tina| Sales Managers

Tel: 0086-20-22093278(CN)

Email: sales@qyresearchglobal.com or tinaning@qyresearch.com

Web: http://www.qyresearchglobal.com/